Minimizing tumor burden by extensive cytoreductive surgery decreases postoperative venous thromboembolism in ovarian clear cell carcinoma

Archives of Gynecology and Obstetrics

Volumn 281, Issue 2, 2010, Pages 329-334

  Lim, Myong Cheol ^a,b   Lee, Hee Seok ^a   Kang, Sokbom ^a   Seo, Sang Soo ^a   Lee, Bo Yon ^b   Park, Sang Yoon ^a  

^a National Cancer Center   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Adenocarcinoma; Clear cell adenocarcinoma; Ovarian cancer; Residual tumor; Surgery; Thromboembolism

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; ENOXAPARIN; FIBRINOGEN; HEMOGLOBIN; IRINOTECAN; MITOMYCIN; PACLITAXEL; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COMPRESSION GARMENT; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG EMBOLISM; OVARY CARCINOMA; PERIOPERATIVE PERIOD; RECURRENT DISEASE; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; TUMOR VOLUME; VENOUS THROMBOEMBOLISM; ADENOCARCINOMA; INCIDENCE; MIDDLE AGED; NONPARAMETRIC TEST; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; VENOUS THROMBOEMBOLISM;

EID: 77950348479     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-1120-2     Document Type: Article

References (29)

1. Trousseau A (1865) Plegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu. Paris 5:281-332
2. Peuscher FW (1981) Thrombosis and bleeding in cancer patients. Neth J Med 24:23-35
3. Gladish GW, Choe DH, Marom EM, SabloV BS, Broemeling LD, Munden RF (2006) Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology 240:246-255. doi:10.1148/radiol.2401051129
4. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C et al (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103:1083-1090. doi:10.1016/j.ygyno. 2006.06.028 (Pubitemid 44821338)
5. Yoshikawa H (2003) Surgical treatment for advanced ovarian cancer. Cancer Res Treat 35:30s
6. Lee AY, Levine MN (1999) The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 25:137-145. doi:10.1055/s-2007-994915 (Pubitemid 29227142)
7. von TempelhoV GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L (1997) Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 77:456-461 (Pubitemid 27121008)
8. Cha SW, Park H, Seong SJ, Kim TJ, Lim KT, Chung HW et al (2003) Clinicopathological characteristics and survival rate of primary clear cell carcinoma of the ovary. Korean J Gynecol Oncol Colposc 14:140-150
9. GoV BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW et al (1996) Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum- based chemotherapy in stage III disease. Gynecol Oncol 60:412-417. doi:10.1006/gyno.1996.0065 (Pubitemid 26077628)
10. Matsuura Y, Robertson G, Marsden DE, Kim SN, Gebski V, Hacker NF (2007) Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 104:406-410. doi:10.1016/j.ygyno.2006.08.026 (Pubitemid 46135653)
11. Recio FO, Piver MS, Hempling RE, Driscoll DL (1996) Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 78:2157-2163. doi:10.1002/(SICI)1097-0142(19961115)78: 10<2 157::AID-CNCR17>3.0.CO;2-Y
12. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T et al (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584-2589. doi:10.1002/1097-0142(20000601)88:11<2584: :AID-CNCR22>3.0.CO; 2-5 (Pubitemid 30331967)
13. Tateo S, Mereu L, Salamano S, Klersy C, Barone M, Spyropoulos AC et al (2005) Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 99:119-125. doi:10.1016/j.ygyno.2005.05.009 (Pubitemid 41354592)
14. Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH (2007) Venous thromboembolism in ovarian cancer. Gynecol Oncol 105:784-790. doi:10.1016/j.ygyno.2007.02.024 (Pubitemid 46734211)
15. Serov S, Scully R, Sobin L (1973) International histologic classification of tumours, no.9. Histologic typing of ovarian tumours. World Health Organization, Geneva
16. Pecorelli SOF, Maisonneuve P, Creasman W, Shepherd J, Sideri M, Benedet J (1998) Carcinoma of the ovary. Carcinoma of ovary. Annual report on the results of treatment of gynaecological cancer. FIGO annual report of the results of treatment in gynaecological cancer. Carcinoma of the ovary. J Epidemiol Biostat 3:75-102
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216. doi:10.1093/jnci/92.3.205
18. Rustin GJ (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21:187s-193s. doi:10.1200/JCO.2003.01.223
19. Stein PD, Kayali F, Olson RE, Milford CE (2004) Pulmonary thromboembolism in Asians/PaciWc Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 116:435-442. doi:10.1016/j.amjmed.2003.11.020 (Pubitemid 38388612)
20. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505. doi:10.1200/JCO.2007.14.1283 (Pubitemid 350232226)
21. Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR et al (2004) Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94:650-654. doi:10.1016/j.ygyno.2004.01.029 (Pubitemid 39194456)
22. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival Effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248-1259. doi:10.1200/JCO.20.5.1248 (Pubitemid 34177431)
23. Noble S, Shelley M, Coles B, Williams A, Johnson M (2008) Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 9:577-584. doi:10.1016/S1470-2045(08)70149-9 (Pubitemid 351735054)
24. Satoh T, Oki A, Uno K, Sakurai M, Ochi H, Okada S et al (2007) High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer 97:1053-1057. doi:10.1038/sj.bjc.6603989 (Pubitemid 47587007)
25. Crippa L, D'Angelo SV, Tomassini L, Rizzi B, D'Alessandro G, D'Angelo A (1997) The utility and cost-Effectiveness of D-dimer measurements in the diagnosis of deep vein thrombosis. Haematologica 82:446-451 (Pubitemid 28023283)
26. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI et al (1992) The clinical course of pulmonary embolism. N Engl J Med 326:1240-1245
27. Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC et al (2004) Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94:197-203. doi:10.1016/j.ygyno. 2004.04.004
28. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR et al (1988) Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 159:341-346
29. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D et al (2006) Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 102:285-291. doi:10.1016/j.ygyno.2005.12.038 (Pubitemid 44041640)